Alan F. List, MD, on Rigosertib in Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome

2014 ASH Annual Meeting

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 163, “Overall Survival and Subgroup Analysis From a Randomized Phase III Study of Intravenous Rigosertib vs Best Supportive Care in Patients With Higher-Risk Myelodysplastic Syndrome After Failure of Hypomethylating Agents,” presented by Guillermo Garcia-Manero, MD.

Time: 1:54

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinical trials: different doses of daunorubicin for AML; comparing azacitidine plus lenolidomide to vorinostat vs azacitidine monotherapy in MDS and CMML; and sorafenib vs placebo in addition to standard treatment for AML.

Hematologic Malignancies

Ayalew Tefferi, MD

Time: 1:53

Hematologic Malignancies

Linda J. Burns, MD

Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 53, “ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults With Beta-Thalassemia: Preliminary Results From a Phase II Study,” presented by Antonio G. Piga, MD.

Jun

Today In Oncology

Alan F. List, MD, on Rigosertib in Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome

Related Videos

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis

Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial

Bertrand Coiffier, MD, PhD, on the RO-CHOP Study

Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia

Sacituzumab Govitecan and Pembrolizumab Improve Disease Control in Advanced PD-L1-Positive TNBC

Vepdegestrant Improves PFS in Select Patients With ESR1-Mutant Advanced Breast Cancer

Impact of Wildfire Related Pollution on Survival in NSCLC

Trastuzumab Deruxtecan Improves Survival Outcomes in Patients With HER2-Positive Gastric-GEJ Cancer

Molecular Assay Identifies Patients With Early NSCLC Likely to Benefit From Adjuvant Chemotherapy